M Clerico Selected Research

Multiple Sclerosis

11/2009	Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
10/2009	Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
4/2009	Neutralizing antibodies in multiple sclerosis patients treated with 375 micrograms interferon-beta-1b.
6/2008	MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis.
4/2008	Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
2/2006	Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Clerico Research Topics

Disease

6	Multiple Sclerosis 11/2009 - 02/2006
2	Relapsing-Remitting Multiple Sclerosis 04/2008 - 04/2001
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2000
1	Lung Neoplasms (Lung Cancer) 10/2000
1	Brain Neoplasms (Brain Tumor) 10/2000
1	Neoplasms (Cancer) 10/2000

Drug/Important Bio-Agent (IBA)

5	Interferon-betaIBA 11/2009 - 04/2001
1	Neutralizing AntibodiesIBA 04/2009
1	InterferonsIBA 06/2008
1	Immunomodulating AgentsIBA 04/2008
1	Glatiramer Acetate (Copaxone)FDA Link 04/2008
1	Interferon beta-1b (Betaseron)FDA Link 02/2006
1	Interferon beta-1a FDA Link 02/2006
1	Teniposide (VM 26)FDA Link 10/2000

Therapy/Procedure

2	Therapeutics 10/2009 - 10/2000
1	Drug Therapy (Chemotherapy) 10/2000
1	Radiotherapy 10/2000